The Central Drugs Standard Control Organisation (CDSCO) has released draft guidelines aimed at implementing good distribution practices within the pharmaceutical industry to prevent the circulation of spurious, adulterated, and sub-standard products in the market. These guidelines align with the WHO Technical Report Series (TRS) on good storage and distribution practices for pharmaceuticals.

The objective of these guidelines is to establish and maintain a robust quality system throughout the distribution process, from the manufacturer's premises to the end recipient, ensuring the safety and efficacy of pharmaceutical products.

Key Highlights of the Draft Guidelines:

Establishment of Quality System: Pharmaceutical product distributors are mandated to establish and maintain a comprehensive quality system. Each distribution site must appoint a responsible person designated by management to oversee the implementation and maintenance of the quality system.

Documented Procedures and Deviations: The guidelines emphasize the documentation of established procedures and the investigation of any deviations encountered during distribution. Deviations must be appropriately documented and investigated, with corrective and preventive actions (CAPA) implemented to rectify deviations and prevent their recurrence.

Product Recall Procedures: In cases where product recall is necessary, the guidelines stipulate that recalled products must be segregated during transit and clearly labeled as such. If segregation is not feasible during transit, recalled goods should be securely packaged, labeled, and accompanied by appropriate documentation.

Prompt Communication on Product Recall: All customers and competent authorities in countries where the product has been distributed must be promptly informed of any intention to recall a pharmaceutical product.

Disposal of Returned Products: Returned products should be destroyed in accordance with international, national, and local requirements, considering environmental protection. Returned products can only be retained if their quality is confirmed to be satisfactory through a documented and authorized procedure.

Dispatch Records and Traceability: Detailed records of product dispatches must include essential information such as product description, dosage form, strength, quantity, batch number, and expiry date. These records should enable the traceability of pharmaceutical products throughout the distribution process.

The draft guidelines showcases the critical importance of maintaining high standards in pharmaceutical distribution to safeguard public health and safety. By implementing these guidelines effectively, stakeholders across the supply chain can contribute to ensuring the integrity and quality of pharmaceutical products reaching patients and healthcare providers.

It is essential for all involved parties to adhere to these guidelines to prevent the introduction of sub-standard products into the market and uphold the highest standards of quality assurance in pharmaceutical distribution. These measures are imperative in safeguarding public health and maintaining consumer confidence in the pharmaceutical industry.